68Ga-NYM096 not checked

Norroy Bioscience Co., LTD

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Using a syringe to withdraw 68Ga-NYM096 injection, the dose will be administered via an intravenous injection”In the company’s words, NCT07768306 on ClinicalTrials.gov
Tested for
Clear Cell Renal Cell Carcinoma (ccRCC)
Main trialPhase 1
“68Ga-NYM096 is a carbonic anhydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for the detection of clear cell renal cell carcinoma (ccRCC). The Phase 1 study is to evaluate the safety, pharmacokinetics, radioactivity distribution, radiation safety and preliminary diagnostic performance in participants with indeterminate renal masses (IRM)”In the company’s words, NCT07768306 on ClinicalTrials.gov

Other drugs for Clear Cell Renal Cell Carcinoma (ccRCC)

All 126 drugs for Clear Cell Renal Cell Carcinoma (ccRCC)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting Mar 2027 Evaluation of Safety, Pharmacokinetics, Distribution,Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow 68Ga-NYM096

Following is part of Solo: you see every change to 68Ga-NYM096 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in